Novo Nordisk cans two more trials of IL-6 heart drug for futility

Novo Nordisk has ended work early on two more late-stage studies of its IL-6 inhibitor ziltivekimab after the studies’ data monitoring committee determined there was little chance of them succeeding. A spokesperson told Endpoints News ...